Mira announces DEA ruling on MIRA-55 as a not controlled substance

MIRA Pharmaceuticals announced that MIRA-55, has been determined by the U.S. Drug Enforcement Administration, or DEA, not to be a controlled substance or listed chemical under the Controlled Substance Act and its governing regulations. MIRA-55 is under investigation for treating adult patients suffering from neuropathic pain as well as anxiety and cognitive decline often associated with early-stage dementia. Unlike THC, which can impair cognitive function, MIRA-55 has demonstrated in pre-clinical studies that it can improve memory by 100% in wild-type mice. MIRA-55 has shown promising results in enhancing memory and cognitive performance in preclinical models. Unlike THC found in marijuana, which exhibits a biphasic effect, MIRA55 demonstrates a monophasic dose-response in pre-clinical models, indicating a more stable and consistent anti-anxiety effect across its dosage range. MIRA-55 exhibits lower potency at the CB1 receptor, which is responsible for the psychoactive effects of THC, while maintaining higher activation of the CB2 receptor. This suggests that MIRA-55 may deliver therapeutic benefits with minimal intoxicating effects.